Thus, a safe, effective, and precise in vivo delivery strategy is urgently needed for the systematic application of CRISPR/Cas9 gene‐editing therapy.[15, 47] In the present study, we knocked out GDF15 in HCC tumors in vivo using the CRISPR/Cas9 system, which is mediated by nanocapsules and achieved excellent efficacy. This evidence concerns the gene GDF15 and hepatocellular carcinoma.